Janssen-Cilag International NV Withdraws Its Marketing Authorisation Application For Comfyde (Carisbamate), Europe
Janssen-Cilag International NV Withdraws Its Marketing Authorisation Application For Comfyde (Carisbamate), Europe
The European Medicines Agency has been formally notified by Janssen-Cilag International NV of its decision to withdraw its application for a centralised marketing authorisation for the medicine Comfyde (carisbamate) 100mg, 200mg, 400mg and 600mg film-coated tablets. This medicine was intended to be used for adjunctive treatment of partial onset seizures with or without secondary generalisation …
Read more on Medical News Today
Author: Worldprofit
This author has published 3414 articles so far. More info about the author is coming soon.